Asthma And Copd Drugs Market By Drug Class (bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, Combination Drugs) And Indication (asthma And Copd) - Global Industry Analysis And Forecast To 2023
Published On : June 2022 Pages : 190 Category: Pharmaceuticals Report Code : HC061015
Industry Outlook and Trend Analysis
The Asthma and COPD Drugs Market was worth USD 12.58 billion in 2017 and is expected to reach approximately USD 17.99 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 4.05% during the forecast period. Asthma is an illness described by repetitive assaults of hacking, chest-fixing, windedness, and wheezing as the airways becomes thin and swell that differ in seriousness and recurrence. COPD is an ailment of the lungs portrayed by impediment to wind current that meddles with ordinary relaxing. As per the WHO, COPD represented more than 3 million passing’s in 2017, which is equivalent to 6% of all passing’s all inclusive in that year. Also, the WHO predicts that COPD will turn into the third most regular reason for death internationally by 2030. In any case, these insights have just emerged in the U.S. also, China, where COPD is as of now said to be the third driving reason for mortality.
Drivers & Restrains
Increment in predominance of COPD and asthma patients; increment in world maturing populace, innovative progression in the treatment of asthma and COPD, increment in pipeline items development in activities actualized by the legislature and non-government relationship for ascend in wellbeing awareness are the main considerations that drive the development of the Asthma and COPD Drug. However, stringent government administrative prerequisite for the endorsement of asthma and COPD drugs, the asthma and COPD drugs indicating reactions, patent expiry of the medications limit the market development. Moreover, developing nations, for example, China and India, furnish enormous development openings alongside acquaintance of bland medications with this market.
Regional Outlook and Trend Analysis
North America held the biggest share of the market in 2017. Development rates for each fragment inside the U.S. and China asthma and COPD drugs market have been resolved after a careful examination of past patterns, socioeconomics, future patterns, mechanical advancements, medicate improvement life cycle, and administrative necessities. These components would help the market players to take key choices keeping in mind the end goal to reinforce their positions and grow their offer in the asthma and COPD drugs market in the U.S and China.
Competitive Insights
The leading players in the market are GlaxoSmithKline (GSK), Novartis AG, Merck & Co., Abbott Laboratories, Boehringer Ingelheim and others. Many Key players are depending on methods, for example, agreements & joint ventures, collaborations, and advancements to build the visibility of their products and fortify their product portfolios.
The Asthma and COPD Drugs Market is segmented as follows-
By Drug Class:
- Bronchodilators
- Anti-inflammatory Drugs
- Monoclonal Antibodies
- Combination Drugs
By Indication:
- Asthma
- COPD
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- South Africa
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2023?
- What will be the industry market growth from 2017 to 2023?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Asthma and COPD Drugs Market, By Drug Class, Estimates and Forecast, 2014-2023 ($Million)
· Bronchodilators
· Anti-inflammatory Drugs
· Monoclonal Antibodies
· Combination Drugs
· Asthma and COPD Drugs Market, By Indication, Estimates and Forecast, 2014-2023 ($Million)
· Asthma
· COPD
· Asthma and COPD Drugs Market, By Region, Estimates and Forecast, 2014-2023 ($Million)
· North America
§ North America Asthma and COPD Drugs Market, By Country
o U.S. Asthma and COPD Drugs Market
o Canada Asthma and COPD Drugs Market
o Mexico Asthma and COPD Drugs Market
· Europe
§ Europe Asthma and COPD Drugs Market, By Country
o Germany Asthma and COPD Drugs Market
o UK Asthma and COPD Drugs Market
o France Asthma and COPD Drugs Market
o Russia Asthma and COPD Drugs Market
o Italy Asthma and COPD Drugs Market
o Rest of Europe Asthma and COPD Drugs Market
· Asia-Pacific
§ Asia-Pacific Asthma and COPD Drugs Market, By Country
o China Asthma and COPD Drugs Market
o Japan Asthma and COPD Drugs Market
o South Korea Asthma and COPD Drugs Market
o India Asthma and COPD Drugs Market
o Southeast Asia Asthma and COPD Drugs Market
o Rest of Asia-Pacific Asthma and COPD Drugs Market
· South America
§ South America Asthma and COPD Drugs Market
o Brazil Asthma and COPD Drugs Market
o Argentina Asthma and COPD Drugs Market
o Columbia Asthma and COPD Drugs Market
o South Africa Asthma and COPD Drugs Market
o Rest of South America Asthma and COPD Drugs Market
· Middle East and Africa
§ Middle East and Africa Asthma and COPD Drugs Market
o Saudi Arabia Asthma and COPD Drugs Market
o UAE Asthma and COPD Drugs Market
o Egypt Asthma and COPD Drugs Market
o Nigeria Asthma and COPD Drugs Market
o South Africa Asthma and COPD Drugs Market
o Rest of MEA Asthma and COPD Drugs Market
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2017-2023)
4.1.2. Canada Market States and Outlook (2017-2023)
4.1.3. Mexico Market States and Outlook (2017-2023)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2017-2023)
4.2.2. France Market States and Outlook (2017-2023)
4.2.3. UK Market States and Outlook (2017-2023)
4.2.4. Russia Market States and Outlook (2017-2023)
4.2.5. Italy Market States and Outlook (2017-2023)
4.2.6. Rest of Europe Market States and Outlook (2017-2023)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2017-2023)
4.3.2. Japan Market States and Outlook (2017-2023)
4.3.3. Korea Market States and Outlook (2017-2023)
4.3.4. India Market States and Outlook (2017-2023)
4.3.5. Rest of Asia-Pacific Market States and Outlook (2017-2023)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2017-2023)
4.4.2. Argentina Market States and Outlook (2017-2023)
4.4.3. Columbia Market States and Outlook (2017-2023)
4.4.4. Rest of South America Market States and Outlook (2017-2023)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2017-2023)
4.5.2. UAE Market States and Outlook (2017-2023)
4.5.3. Egypt Market States and Outlook (2017-2023)
4.5.4. Nigeria Market States and Outlook (2017-2023)
4.5.5. South Africa Market States and Outlook (2017-2023)
4.5.6. Rest of MEA Market States and Outlook (2017-2023)
5. Asthma and COPD Drugs Market, By Drug Class
5.1. Introduction
5.2. Global Asthma and COPD Drugs Sales, Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Asthma and COPD Drugs Sales and Sales Share by Drug Class (2017-2027)
5.2.2. Global Asthma and COPD Drugs Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Bronchodilators
5.3.1. Global Bronchodilators Sales and Growth Rate (2017-2027)
5.4. Anti-inflammatory Drugs
5.4.1. Global Anti-inflammatory Drugs Sales and Growth Rate (2017-2027)
5.5. Monoclonal Antibodies
5.5.1. Global Monoclonal Antibodies Sales and Growth Rate (2017-2027)
5.6. Combination Drugs
5.6.1. Global Combination Drugs Sales and Growth Rate (2017-2027)
6. Asthma and COPD Drugs Market, By Indication
6.1. Introduction
6.2. Global Asthma and COPD Drugs Sales, Revenue and Market Share by Indication (2017-2027)
6.2.1. Global Asthma and COPD Drugs Sales and Sales Share by Indication (2017-2027)
6.2.2. Global Asthma and COPD Drugs Revenue and Revenue Share by Indication (2017-2027)
6.3. Asthma
6.3.1. Global Asthma Sales and Growth Rate (2017-2027)
6.4. COPD
6.4.1. Global COPD Sales and Growth Rate (2017-2027)
7. Asthma and COPD Drugs Market, By Region
7.1. Introduction
7.2. Global Asthma and COPD Drugs Sales, Revenue and Market Share by Regions
7.2.1. Global Asthma and COPD Drugs Sales by Regions (2017-2027)
7.2.2. Global Asthma and COPD Drugs Revenue by Regions (2017-2027)
7.3. North America Asthma and COPD Drugs by Countries
7.3.1. North America Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.3.2. North America Asthma and COPD Drugs Revenue and Growth Rate (2017-2027)
7.3.3. North America Asthma and COPD Drugs Sales by Countries (2017-2027)
7.3.4. North America Asthma and COPD Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.5. U.S.
7.3.5.1. United States Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.3.5.2. United States Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.6. Canada
7.3.6.1. Canada Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.3.6.2. Canada Asthma and COPD Drugs Sales (Millions USD) and Growth Rate (2017-2027)
7.3.7. Mexico
7.3.7.1. Mexico Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.3.7.2. Mexico Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Asthma and COPD Drugs by Countries
7.4.1. Europe Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.4.2. Europe Asthma and COPD Drugs Revenue and Growth Rate (2017-2027)
7.4.3. Europe Asthma and COPD Drugs Sales by Countries (2017-2027)
7.4.4. Europe Asthma and COPD Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.5. Germany
7.4.5.1. Germany Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.4.5.2. Germany Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. UK
7.4.6.1. UK Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.4.6.2. UK Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. France
7.4.7.1. France Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.4.7.2. France Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Russia
7.4.8.1. Russia Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.4.8.2. Russia Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.9. Italy
7.4.9.1. Italy Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.4.9.2. Italy Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.10. Rest of Europe
7.4.10.1. Rest of Europe Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.4.10.2. Rest of Europe Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific
7.5.1. Asia-Pacific Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Asthma and COPD Drugs Revenue and Growth Rate (2017-2027)
7.5.3. Asia-Pacific Asthma and COPD Drugs Sales by Countries (2017-2027)
7.5.4. Asia-Pacific Asthma and COPD Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.5. China
7.5.5.1. China Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.5.5.2. China Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. Japan
7.5.6.1. Japan Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.5.6.2. Japan Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6.3.
7.5.7. Korea
7.5.7.1. Korea Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.5.7.2. Korea Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. India
7.5.8.1. India Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.5.8.2. India Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.9. Southeast Asia
7.5.9.1. Southeast Asia Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.5.9.2. Southeast Asia Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.10. Rest of Asia-Pacific
7.5.10.1. Rest of Asia-Pacific Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.5.10.2. Rest of Asia-Pacific Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America
7.6.1. South America Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.6.2. South America Asthma and COPD Drugs Revenue and Growth Rate (2017-2027)
7.6.3. South America Asthma and COPD Drugs Sales by Countries (2017-2027)
7.6.4. South America Asthma and COPD Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.5. Brazil
7.6.5.1. Brazil Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.6.5.2. Brazil Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Argentina
7.6.6.1. Argentina Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.6.6.2. Argentina Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.7. Columbia
7.6.7.1. Columbia Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.6.7.2. Columbia Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.8. Rest of South America
7.6.8.1. Rest of South America Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.6.8.2. Rest of South America Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa
7.7.1. Middle East and Africa Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Asthma and COPD Drugs Revenue and Growth Rate (2017-2027)
7.7.3. Middle East and Africa Asthma and COPD Drugs Sales by Countries (2017-2027)
7.7.4. Middle East and Africa Asthma and COPD Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.7.5.2. Saudi Arabia Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. United Arab Emirates
7.7.6.1. United Arab Emirates Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.7.6.2. United Arab Emirates Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. Egypt
7.7.7.1. Egypt Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.7.7.2. Egypt Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Nigeria
7.7.8.1. Nigeria Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.7.8.2. Nigeria Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. South Africa
7.7.9.1. South Africa Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.7.9.2. South Africa Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.10. Rest of Middle East and Africa
7.7.10.1. Rest of Middle East and Africa Asthma and COPD Drugs Sales and Growth Rate (2017-2027)
7.7.10.2. Rest of Middle East and Africa Asthma and COPD Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. AstraZeneca plc
8.1.1. Business Overview
8.1.2. Product Portfolio
8.1.3. Strategic Developments
8.1.4. Sales, Revenue and Market Share
8.2. Boehringer Ingelheim GmbH
8.2.1. Business Overview
8.2.2. Product Portfolio
8.2.3. Strategic Developments
8.2.4. Sales, Revenue and Market Share
8.3. F Hoffmann-La Roche Ltd.
8.3.1. Business Overview
8.3.2. Product Portfolio
8.3.3. Strategic Developments
8.3.4. Sales, Revenue and Market Share
8.4. GlaxoSmithKline plc
8.4.1. Business Overview
8.4.2. Product Portfolio
8.4.3. Strategic Developments
8.4.4. Sales, Revenue and Market Share
8.5. Merck & Co., Inc.
8.5.1. Business Overview
8.5.2. Product Portfolio
8.5.3. Strategic Developments
8.5.4. Sales, Revenue and Market Share
8.6. Novartis AG
8.6.1. Business Overview
8.6.2. Product Portfolio
8.6.3. Strategic Developments
8.6.4. Sales, Revenue and Market Share
9. Global Asthma and COPD Drugs Market Competition, by Manufacturer
9.1. Global Asthma and COPD Drugs Sales and Market Share by Manufacturer (2017-2017)
9.2. Global Asthma and COPD Drugs Revenue and Market Share by Manufacturer (2017-2017)
9.3. Global Asthma and COPD Drugs Price by Manufacturer (2017-2017)
9.4. Top 5 Asthma and COPD Drugs Manufacturer Market Share
9.5. Market Competition Trend
10. Asthma and COPD Drugs Market Forecast (2027-2023)
10.1. Global Asthma and COPD Drugs Sales, Revenue (Millions USD) and Growth Rate (2027-2023)
10.2. Asthma and COPD Drugs Market Forecast by Regions (2027-2023)
10.2.1. North America Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.1.1. United States Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.1.2. Canada Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.1.3. Mexico Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.2. Europe Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.2.1. Germany Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.2.2. United Kingdom Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.2.3. France Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.2.4. Russia Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.2.5. Italy Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.2.6. Rest of the Europe Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.3. Asia-Pacific Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.3.1. China Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.3.2. Japan Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.3.3. Korea Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.3.4. India Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.3.5. Southeast Asia Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.3.6. Rest of Asia-Pacific Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.4. South America Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.4.1. Brazil Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.4.2. Argentina Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.4.3. Columbia Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.4.4. Rest of South America Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.5. Middle East and Africa Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.5.1. Saudi Arabia Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.5.2. UAE Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.5.3. Egypt Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.5.4. Nigeria Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.5.5. South Africa Asthma and COPD Drugs Market Forecast (2027-2023)
10.2.5.6. Rest of MEA Asthma and COPD Drugs Market Forecast (2027-2023)
10.3. Asthma and COPD Drugs Market Forecast by Drug Class (2027-2023)
10.3.1. Global Asthma and COPD Drugs Sales Forecast by Drug Class (2027-2023)
10.3.2. Global Asthma and COPD Drugs Sales Market Share Forecast by Drug Class (2027-2023)
10.4. Asthma and COPD Drugs Market Forecast by Indication (2027-2023)
10.4.1. Global Asthma and COPD Drugs Sales Forecast by Indication (2027-2023)
10.4.2. Global Asthma and COPD Drugs Sales Market Share Forecast by Indication (2027-2023)
List of Tables
*You can glance through the list of Tables and Figures when you view the sample copy of Asthma and COPD Drugs Market.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|